Routine Axillary Ultrasound for Patients with T1 –T2 Breast Cancer Does Not Increase the Rate of Axillary Lymph Node Dissection Based on Predictive Modeling

DiscussionUse of AUS may help to tailor patient care without leading to overutilization of ALND, as long as neoadjuvant chemotherapy is administered when appropriate.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSIONS: HER2Bi- or EGFRBi-armed CART19 exhibited specific cytotoxicity against multiple HER2+/EGFR+/CD19- tumor targets in overnight and long-term serial killing assays. CART19 showed improved survival and were resistant to exhaustion after prolonged repeated exposure to tumor cells. PMID: 32449004 [PubMed - indexed for MEDLINE]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
This article explores and reports on the data used to make this policy amendment. PMID: 32657737 [PubMed - as supplied by publisher]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
Pesantez Maria Vidal Barbara Adamo Montserrat Muñoz Patricia Galván Laura Barberá Miriam Cuatrecasas Mathias Christgen Hans Kreipe Inés Monge-Escartín Patricia Villagrasa Dolors Soy Tommaso Giarratano Maria Vittoria Dieci Pierfranco Conte Nadia Harbeck Valentina Guarneri Aleix Prat Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conclusion: In large high-quality data, BB use at the time of anti-HER2 therapy initiation for ABC was independently associated with worse OS, regardless of CVD status. The finding is contrary to pre-study hypotheses and findings in other BC subtypes. Future research should aim to gain a deeper understanding of the effects of BBs on specific BC subtypes, cancer types, and cancer treatments.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   HER2 Positive Breast Cancer Intervention:   Drug: AIP-303 Sponsors:   Advanced Imaging Projects, LLC;   All India Institute of Medical Sciences, New Delhi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Patient age has a significant influence if elderly patients with axillary disease receive radiotherapy. Further investigation and validation are needed to understand why chronological age rather than biological age influences treatment modalities.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a n...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
SummaryAt the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase  3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a  pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was m...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Modern Pathology, Published online: 13 July 2020; doi:10.1038/s41379-020-0620-2Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study
Source: Modern Pathology - Category: Pathology Authors: Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c07353
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
More News: Biology | Breast Cancer | Breast Needle Aspiration | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ultrasound